FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-677.02M
-480.47M
-312.74M
-150.08M
Net Income
-230.86M
-188.82M
-162.04M
-160.46M
Stock Repurchases
0
0
0
-122k
Dividend Paid
0
0
0
0
Retained Earnings
-856.68M
-677.02M
-480.47M
-312.74M
Other Distributions
-179.67M
-196.55M
-167.73M
-162.78M
All figures are in USD.
